These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2513156)

  • 21. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?
    Fatourechi V; Hay ID; Mullan BP; Wiseman GA; Eghbali-Fatourechi GZ; Thorson LM; Gorman CA
    Thyroid; 2000 Jul; 10(7):573-7. PubMed ID: 10958309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surveillance of patients to detect recurrent thyroid carcinoma.
    Grigsby PW; Baglan K; Siegel BA
    Cancer; 1999 Feb; 85(4):945-51. PubMed ID: 10091774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.
    Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ
    J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi].
    Kukulska A; Krajewska J; Roskosz J; Handkiewicz-Junak D; Jarzab M; Paliczka E; Puch Z; Wygoda Z; Gubała E; Jarzab B
    Endokrynol Pol; 2006; 57(4):374-9. PubMed ID: 17006839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-operative diagnosis and therapy of thyroid carcinoma by nuclear medicine.
    Hundeshagen H
    Eur J Nucl Med; 1983; 8(12):541-5. PubMed ID: 6667704
    [No Abstract]   [Full Text] [Related]  

  • 27. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer.
    Chen MK; Yasrebi M; Samii J; Staib LH; Doddamane I; Cheng DW
    Thyroid; 2012 Mar; 22(3):304-9. PubMed ID: 22300251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours.
    Gerard SK; Cavalieri RR
    Clin Nucl Med; 2002 Jan; 27(1):1-8. PubMed ID: 11805475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131.
    Park HM; Perkins OW; Edmondson JW; Schnute RB; Manatunga A
    Thyroid; 1994; 4(1):49-54. PubMed ID: 8054861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
    Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
    J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency of hepatic visualization during I-131 imaging for metastatic thyroid carcinoma.
    Rosenbaum RC; Johnston GS; Valente WA
    Clin Nucl Med; 1988 Sep; 13(9):657-60. PubMed ID: 3180614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unusual patterns of I-131 contamination.
    Ozguven M; Ilgan S; Arslan N; Karacalioglu AO; Yuksel D; Dundar S
    Ann Nucl Med; 2004 May; 18(3):271-4. PubMed ID: 15233290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid carcinoma: iodine-131-negative whole-body scan reverses to positive after a combination of thyrogen stimulation and withdrawal.
    Kasner DL; Spieth ME; Starkman ME; Zdor-North D
    Clin Nucl Med; 2002 Nov; 27(11):772-80. PubMed ID: 12394123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer.
    Samuel AM; Rajashekharrao B; Shah DH
    J Nucl Med; 1998 Sep; 39(9):1531-6. PubMed ID: 9744337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. False-positive I-131 uptake at a tracheostomy site. Discernment with Tl-201 imaging.
    Ain KB; Shih WJ
    Clin Nucl Med; 1994 Jul; 19(7):619-21. PubMed ID: 7924106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases.
    Yaakob W; Gordon L; Spicer KM; Nitke SJ
    J Nucl Med Technol; 1999 Dec; 27(4):279-81. PubMed ID: 10646545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discordant findings of Iodine-131 scintiscan and chest radiogram in carcinoma of thyroid patients.
    Rajani AT; Rao PN; Devaru S; Mamathadevi S
    Indian J Cancer; 2001; 38(2-4):121-5. PubMed ID: 12593450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.